Hearscape
Therapies database

Find a therapy. Follow the evidence.

See what is being studies, who is developing it, and how far it has progressed.

Search therapy records

Search a therapy, company, target, indication, or trial ID. Narrow by approach, stage, or status, then open a record to check its sources.

More filters and sort (2 active)
3 results
SENS-401 (Arazasetron) by Sensorion
Sensorion · Small Molecule · Phase 2
ActiveTherapeuticStronger sources
Population
Adults · ≥18 years
SSNHL, cisplatin, or cochlear-implant cohorts
Evidence
company
Confidence
94%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCisplatin-Induced Hearing Loss
Details
SENS-501 by Sensorion
Sensorion · Gene Therapy · Phase 1/2
ActiveTherapeuticStronger sources
Population
Children · 6–31 months
Biallelic OTOF deafness with preserved outer-hair-cell function
Evidence
trial
Confidence
94%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossOTOF-Related Hearing Loss
Details
GJB2-GT by Sensorion
Sensorion · Gene Therapy · Preclinical
ActiveTherapeuticStronger sources
Population
Children & adults · Not yet defined (preclinical)
GJB2-related DFNB1A nonsyndromic deafness
Evidence
company
Confidence
88%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing Loss
Details

A listing is not proof of safety or effectiveness. Approval and availability may vary by indication and country.

How records are checked